Meeting
2022 ASCO Annual Meeting
Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.
Authors
Caio Max Sao Pedro Rocha Lima
Wake Forest University Baptist Medical Center, Winston-Salem, NC
Caio Max Sao Pedro Rocha Lima , Greg Yothers , Samuel A. Jacobs , Hanna Kelly Sanoff , Deirdre Jill Cohen , Katherine A Guthrie , Norah Lynn Henry , Patricia A. Ganz , Scott Kopetz , Peter C. Lucas , Charles David Blanke , Theodore S. Hong , Norman Wolmark , Howard S. Hochster , Thomas J. George , Michael J. Overman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT02997228
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3647)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3647
Abstract #
TPS3647
Poster Bd #
431b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Michael J. Overman
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Caio Max Sao Pedro Rocha Lima
First Author: James J. Lee
First Author: Michael J. Overman